April 2024
1. SALLEE L, Souchet L, Boutolleau D, Nguyen S, et al
   Amenamevir for Treating Acyclovir-Resistant or Refractory Herpes Simplex Virus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Two Case Reports.
   Int J Antimicrob Agents. 2024 Apr 10:107169.
   

   >> Share

   
   
2. VO T, Pontarotti P, Rolain JM, Merhej V, et al
   Mechanisms of acquisition of vanA operon among vancomycin-resistant Staphylococcus aureus genomes: the tip of the iceberg?
   Int J Antimicrob Agents. 2024 Apr 8:107154.
   

   >> Share

   
   
3. GILL K, Takamichi B, Cooper A
   Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: new data from CREDIBLE-CR with an updated meta-analysis.
   Int J Antimicrob Agents. 2024 Apr 4:107167.
   

   >> Share

   
   
4. GATTI M, Cosentino F, Giannella M, Viale P, et al
   In reply to the Letter to the Editor regarding "Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis".
   Int J Antimicrob Agents. 2024 Apr 4:107168.
   

   >> Share

   
   
5. MONTE DFM, de Oliveira CJB
   A 22-year Brazilian colistin resistance surveillance on Escherichia coli and Salmonella spp. originating from food-producing animals.
   Int J Antimicrob Agents. 2024;63:107114.
   

   >> Share

   
   March 2024
6. HU J, Zha L, Yu YW, Su Q, et al
   Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections: focus on Solid Organ Transplantation Recipients.
   Int J Antimicrob Agents. 2024 Mar 19:107152.
   

   >> Share

   
   
7. HO LC, Yu Chi C, You YS, Hsieh YW, et al
   Impact of the implementation of the Intelligent Antimicrobial System (iAMS) on clinical outcomes among patients with bacteraemia caused by methicillin-resistant Staphylococcus aureus.
   Int J Antimicrob Agents. 2024 Mar 13:107142.
   

   >> Share

   
   February 2024
8. KHARAT AS, Makwana N, Nasser M, Gayen S, et al
   Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
   Int J Antimicrob Agents. 2024 Feb 29:107125.
   

   >> Share

   
   
9. WANG C, Bai C, Chen K, Du Q, et al
   International guidelines for the treatment of carbapenem-resistant Gram-negative bacilli infections: a comparison and evaluation.
   Int J Antimicrob Agents. 2024 Feb 26:107120.
   

   >> Share

   
   
10. BOATTINI M, Bianco G, Llorente LI, Acero LA, et al
    Enterobacterales carrying chromosomal AmpC beta-lactamases in Europe (EuESCPM): epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020-2022.
    Int J Antimicrob Agents. 2024 Feb 15:107115.
    

    >> Share

    
    
11. YANG L, Gao Y, Zhang J, Tian C, et al
    Antimicrobial peptide DvAMP combats carbapenem-resistant Acinetobacter baumannii infection.
    Int J Antimicrob Agents. 2024 Feb 5:107106.
    

    >> Share

    
    
12. WANG JL, Lai CC, Tsai YW, Ko WC, et al
    High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-2021.
    Int J Antimicrob Agents. 2024 Feb 5:107105.
    

    >> Share

    
    
13. SIVAY MV, Maksimenko LV, Nalimova TM, Nefedova AA, et al
    HIV drug resistance among patients experiencing antiretroviral therapy failure in Russia, 2019-2021.
    Int J Antimicrob Agents. 2024;63:107074.
    

    >> Share

    
    
14. CHEN H, Hu P, Liu H, Liu S, et al
    Combining with domiphen bromide restores colistin efficacy against colistin-resistant Gram-negative bacteria in vitro and in vivo.
    Int J Antimicrob Agents. 2024;63:107066.
    

    >> Share

    
    
15. WANG C, Zhang T, Wang Y, Wang Y, et al
    Proguanil and chlorhexidine augment the antibacterial activities of clarithromycin and rifampicin against Acinetobacter baumannii.
    Int J Antimicrob Agents. 2024;63:107065.
    

    >> Share

    
    January 2024
16. FENG Y, Fang Q, Luo H, Li J, et al
    Safety and efficacy of a phage cocktail on murine wound infections caused by carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024 Jan 11:107088.
    

    >> Share

    
    
17. HSUEH CC, Lai CC, Tsai YW, Ko WC, et al
    Poor in vitro activity of ceftazidime/avibactam against carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
    Int J Antimicrob Agents. 2024 Jan 11:107087.
    

    >> Share

    
    
18. HERSHKO Y, Rannon E, Adler A, Burstein D, et al
    WarA, a remote homolog of NpmA and KamB from Nocardia wallacei, confers broad spectrum aminoglycoside resistance in Nocardia and Mycobacteria.
    Int J Antimicrob Agents. 2024 Jan 11:107089.
    

    >> Share

    
    
19. MUSHTAQ S, Vickers A, Woodford N, Livermore DM, et al
    Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.
    Int J Antimicrob Agents. 2024 Jan 2:107081.
    

    >> Share

    
    
20. RATOUIT P, Malet I, Soulie C, Denis J, et al
    HIV-1 resistance mutations to integrase inhibitors impair both integration and reverse transcription steps.
    Int J Antimicrob Agents. 2024;63:107026.
    

    >> Share

    
    
21. PARK S, Choi J, Shin D, Kwon KT, et al
    Conversion to colistin susceptibility by tigecycline exposure in colistin-resistant Klebsiella pneumoniae and its implications to combination therapy.
    Int J Antimicrob Agents. 2024;63:107017.
    

    >> Share

    
    
22. KIM SJ, Shin JH, Kim H, Ko KS, et al
    Roles of crrAB two-component regulatory system in Klebsiella pneumoniae: growth yield, survival in initial colistin treatment stage, and virulence.
    Int J Antimicrob Agents. 2024;63:107011.
    

    >> Share

    
    December 2023
23. DU Y, Wang Y, Geng J, Long J, et al
    Molecular Mechanism of Hfq-dependent sRNA1039 and sRNA1600 Regulating Antibiotic Resistance and Virulence in Shigella sonnei.
    Int J Antimicrob Agents. 2023 Dec 21:107070.
    

    >> Share

    
    
24. YU MC, Huang CK, Hung CS, Wang CH, et al
    Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis.
    Int J Antimicrob Agents. 2023 Dec 9:107053.
    

    >> Share

    
    
25. KIAROSTAMI K, Fernandez-Barat L, Battaglini D, Motos A, et al
    The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia.
    Int J Antimicrob Agents. 2023 Dec 8:107052.
    

    >> Share

    
    
26. JEON E, Kim MK, Park Y
    Efficacy of the bee-venom antimicrobial peptide Osmin against sensitive and carbapenem-resistant Klebsiella pneumoniae strains.
    Int J Antimicrob Agents. 2023 Dec 8:107054.
    

    >> Share

    
    
27. GATTI M, Cosentino F, Giannella M, Viale P, et al
    Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis.
    Int J Antimicrob Agents. 2023 Dec 5:107047.
    

    >> Share

    
    
28. HU T, Wang S, Bing J, Zheng Q, et al
    Hotspot mutations and genomic expansion of ERG11 are major mechanisms of azole resistance in environmental and human commensal isolates of Candida tropicalis.
    Int J Antimicrob Agents. 2023;62:107010.
    

    >> Share

    
    November 2023
29. WANG SH, Yang KY, Sheu CC, Lin YC, et al
    Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: a multicenter retrospective propensity score-matched study.
    Int J Antimicrob Agents. 2023 Nov 29:107044.
    

    >> Share

    
    
30. KUANG SF, Xiang J, Chen YT, Peng XX, et al
    Exogenous pyruvate promotes gentamicin uptake to kill antibiotic-resistant Vibrio alginolyticus.
    Int J Antimicrob Agents. 2023 Nov 17:107036.
    

    >> Share

    
    
31. MUKHOPADHYAY S, Zhang P, To KKW, Liu Y, et al
    Sequential treatment effects on phage-antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023;62:106951.
    

    >> Share

    
    October 2023
32. XU C, Zeng F, Huang Y, Xu Q, et al
    Clinical Efficacy of Ceftazidime/avibactam Combination Therapy for Severe Hospital-acquired Pulmonary Infections Caused by Carbapenem-Resistant and Difficult-to-Treat Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2023 Oct 25:107021.
    

    >> Share

    
    
33. CANTON R, Gottlieb T, Coombs GW, Woo PCY, et al
    Antimicrobial surveillance: a 20-year history of the SMART approach to addressing global antimicrobial resistance into the future.
    Int J Antimicrob Agents. 2023 Oct 20:107014.
    

    >> Share

    
    
34. YU J, Lin HH, Tseng KH, Lin YT, et al
    Prediction of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae from flagged blood cultures by combining rapid Sepsityper MALDI-TOF mass spectra with machine learning.
    Int J Antimicrob Agents. 2023 Oct 4:106994.
    

    >> Share

    
    
35. TAO H, Liu L, Chen X, Peng L, et al
    Coexistence of Klebsiella pneumoniae and Acinetobacter baumannii contributes to antibiotic resistance.
    Int J Antimicrob Agents. 2023 Oct 2:106993.
    

    >> Share

    
    
36. WANG Q, Peng K, Liu Z, Li Y, et al
    Genomic insights into linezolid-resistant Enterococci revealed its evolutionary diversity and poxtA copy number heterogeneity.
    Int J Antimicrob Agents. 2023;62:106929.
    

    >> Share

    
    
37. GUILLAMET MCV, Damulira C, Atkinson A, Fraser VJ, et al
    Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock.
    Int J Antimicrob Agents. 2023;62:106913.
    

    >> Share

    
    September 2023
38. CAI T, Novelli A, Tascini C, Stefani S, et al
    Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: a systematic review and expert opinion.
    Int J Antimicrob Agents. 2023 Sep 23:106983.
    

    >> Share

    
    
39. LIU JY, Jia JJ, Liu M, Duan H, et al
    A novel indolylbenzoquinone compound HL-J6 suppresses biofilm formation and alpha-toxin secretion in methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2023 Sep 21:106972.
    

    >> Share

    
    
40. CAI T, Verze P, Arcaniolo D, Pandolfo SD, et al
    ANTIBIOTIC RESISTANCE PATTERNS AMONG UROPATHOGENS IN FEMALE OUTPATIENTS AFFECTED BY UNCOMPLICATED CYSTITIS: FOCUS ON FOSFOMYCIN TROMETAMOL.
    Int J Antimicrob Agents. 2023 Sep 20:106974.
    

    >> Share

    
    
41. WU JW, Quyen TLT, Hsieh YC, Chen YY, et al
    Investigation of carbapenem-resistant Klebsiella pneumoniae in Taiwan revealed strains co-harboring bla(NDM) and bla(OXA-48-like) and a novel plasmid co-carrying bla(NDM-1) and bla(OXA-181).
    Int J Antimicrob Agents. 2023 Sep 4:106964.
    

    >> Share

    
    
42. SALAMA EA, Eldesouky HE, Elgammal Y, Abutaleb NS, et al
    Lopinavir and ritonavir act synergistically with azoles against Candida auris in vitro and in a mouse model of disseminated candidiasis.
    Int J Antimicrob Agents. 2023;62:106906.
    

    >> Share

    
    
43. ZHAO J, Zhu Y, Han ML, Lu J, et al
    Model-informed dose optimisation of polymyxin-rifampicin combination therapy against multidrug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023;62:106902.
    

    >> Share

    
    
44. HAN Y, Zhang Y, Zeng W, Huang Z, et al
    Synergy with farnesol rejuvenates colistin activity against Colistin-resistant Gram-negative bacteria in vitro and in vivo.
    Int J Antimicrob Agents. 2023;62:106899.
    

    >> Share

    
    
45. SHE Y, Jiang Y, Luo M, Duan X, et al
    Emergence of chromosomally located bla(CTX-M-14b) and qnrS1 in Salmonella enterica serotype Kentucky ST198 in China.
    Int J Antimicrob Agents. 2023;62:106896.
    

    >> Share

    
    
46. WANG C, Tang B, Wu J, Jin X, et al
    Detection of mcr-1-harbouring Escherichia coli by quantum dot labelling of synthetic small peptides mimicking lipopolysaccharide receptors.
    Int J Antimicrob Agents. 2023;62:106898.
    

    >> Share

    
    
47. ZHANG N, Shan W, Gao L, Kou SH, et al
    Repurposing the Hedgehog pathway inhibitor, BMS-833923, as a phosphatidylglycerol-selective membrane-disruptive colistin adjuvant against ESKAPE pathogens.
    Int J Antimicrob Agents. 2023;62:106888.
    

    >> Share

    
    
48. AGYEMAN AA, Lopez-Causape C, Rogers KE, Lucas DD, et al
    Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
    Int J Antimicrob Agents. 2023;62:106887.
    

    >> Share

    
    August 2023
49. NISHIMURA B, Escalante J, Mezcord V, Tuttobene MR, et al
    HSA-induced modifications of Ton-B dependent receptors expression in cefiderocol-exposed carbapenem-resistant Acinetobacter baumannii (CRAB).
    Int J Antimicrob Agents. 2023 Aug 17:106950.
    

    >> Share

    
    
50. JONES DC, LaMartina EL, Lewis JR, Dahl AJ, et al
    One Health and Global Health View of Antimicrobial Susceptibility through the "Eye" of Aeromonas: Systematic Review and Meta-Analysis.
    Int J Antimicrob Agents. 2023;62:106848.
    

    >> Share

    
    July 2023
51. MENG H, Yang J, Niu M, Zhu H, et al
    Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteremia in children: a retrospective study.
    Int J Antimicrob Agents. 2023 Jul 25:106933.
    

    >> Share

    
    
52. WU W, Wei S, Xue CX, Zhang W, et al
    An IncN-ST7 epidemic plasmid mediates the dissemination of carbapenem-resistant Klebsiella pneumoniae in a neonatal intensive care unit over 10 years, China.
    Int J Antimicrob Agents. 2023 Jul 9:106921.
    

    >> Share

    
    
53. DANESHNIA F, Arastehfar A, Lombardi L, Binder U, et al
    Candida parapsilosis isolates carrying mutations outside FKS1 hotspot regions confer high echinocandin tolerance and facilitate the development of echinocandin resistance.
    Int J Antimicrob Agents. 2023;62:106831.
    

    >> Share

    
    
54. YANG S, Peng X, Ren B, Luo Y, et al
    Small molecule II-6s synergises with fluconazole against Candida albicans.
    Int J Antimicrob Agents. 2023;62:106820.
    

    >> Share

    
    June 2023
55. JIANG M, Li X, Xie CL, Chen P, et al
    Fructose enabled killing of antibiotic-resistant Salmonella Enteritidis by gentamicin: Insight from reprogramming metabolomics.
    Int J Antimicrob Agents. 2023 Jun 27:106907.
    

    >> Share

    
    
56. CHOI MH, Kim D, Lee KH, Cho JH, et al
    Changes in the prevalence of hospital-acquired pneumonia-causing bacterial pathogens and the impact of their antimicrobial resistance patterns on clinical outcomes: A propensity score-matched study.
    Int J Antimicrob Agents. 2023 Jun 19:106886.
    

    >> Share

    
    
57. SHENKUTIE AM, Gebrelibanos D, Yao M, Hundie GB, et al
    Impairment of novel non-coding small RNA00203 inhibits biofilm formation and reduces biofilm-specific antibiotic resistance in Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023 Jun 12:106889.
    

    >> Share

    
    
58. KOLLEF M, Dupont H, Greenberg DE, Viale P, et al
    The prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence.
    Int J Antimicrob Agents. 2023 Jun 8:106882.
    

    >> Share

    
    
59. QIAO L, Zuo W, Yang Y, Liu X, et al
    Clinical Outcomes and Safety of Intravenous Polymyxin B-based Treatment in Critically Ill Patients with Carbapenem-resistant Acinetobacter baumannii Nosocomial Pneumonia.
    Int J Antimicrob Agents. 2023 Jun 8:106880.
    

    >> Share

    
    
60. CHEN CL, Janapatla RP, Dudek A, Chen YR, et al
    Functional characterization and clinical implication of a novel epidemic carbapenem-resistant Acinetobacter baumannii genetic marker.
    Int J Antimicrob Agents. 2023 Jun 6:106879.
    

    >> Share

    
    
61. HU H, Shi Q, Zhang P, Quan J, et al
    Prevalence and molecular characteristics of colistin-resistant isolates among clinically isolated carbapenem-resistant Klebsiella pneumoniae in China.
    Int J Antimicrob Agents. 2023 Jun 3:106873.
    

    >> Share

    
    May 2023
62. QU J, Xu J, Liu Y, Hu C, et al
    Real world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
    Int J Antimicrob Agents. 2023 May 27:106872.
    

    >> Share

    
    
63. DING L, Guo Y, Hu F
    Antimicrobial Resistance Surveillance: China's nearly 40-Year Effort.
    Int J Antimicrob Agents. 2023 May 25:106869.
    

    >> Share

    
    
64. GATTI M, Rinaldi M, Tonetti T, Gaibani P, et al
    Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF).
    Int J Antimicrob Agents. 2023 May 14:106852.
    

    >> Share

    
    
65. GARCIA P, Moscoso M, Fernandez MC, Fuentes-Valverde V, et al
    Comparison of the in vivo efficacy of the ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia.
    Int J Antimicrob Agents. 2023 May 5:106836.
    

    >> Share

    
    
66. YANG Q, Zhu Y, Schwarz S, Wang L, et al
    Integrative and conjugative elements in streptococci can act as vectors for plasmids and translocatable units integrated via IS1216E.
    Int J Antimicrob Agents. 2023;61:106793.
    

    >> Share

    
    
67. KARLOWSKY JA, Lob SH, Siddiqui F, Akrich B, et al
    In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
    Int J Antimicrob Agents. 2023;61:106772.
    

    >> Share

    
    
68. LAFFONT-LOZES P, Salipante F, Leguelinel-Blache G, Dunyach-Remy C, et al
    Effect of antimicrobial consumption on Escherichia coli resistance: assessment and forecasting using Dynamic Regression models in a French university hospital (2014-2019).
    Int J Antimicrob Agents. 2023;61:106768.
    

    >> Share

    
    
69. JEAN SS, Liu IM, Hsieh PC, Kuo DH, et al
    Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria.
    Int J Antimicrob Agents. 2023;61:106763.
    

    >> Share

    
    April 2023
70. CAI J, Chen M, Liu Q, Luo J, et al
    Domination of an emerging erythromycin-resistant ptxP3 Bordetella pertussis clone in Shanghai, China.
    Int J Antimicrob Agents. 2023 Apr 29:106835.
    

    >> Share

    
    
71. PLANKAOVA A, Brajerova M, Capek V, Novotna GB, et al
    Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant C. difficile ribotypes 176 and 001 in Slovakia in 2018-2019.
    Int J Antimicrob Agents. 2023 Apr 26:106824.
    

    >> Share

    
    
72. RUSSO A, Bruni A, Gulli S, Borrazzo C, et al
    Efficacy of cefiderocol- versus colistin-containing regimen for treatment of bacteremic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in COVID-19 patients.
    Int J Antimicrob Agents. 2023 Apr 21:106825.
    

    >> Share

    
    
73. HONDA H, Goto T, Uehara Y, Takamatsu A, et al
    Promotion of antimicrobial stewardship following the issuance of the antimicrobial resistance national action plan in Japan: a systematic review of 2016 to 2020.
    Int J Antimicrob Agents. 2023 Apr 21:106829.
    

    >> Share

    
    
74. DE LA FUENTE C, Rodriguez M, Merino N, Carmona P, et al
    Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.
    Int J Antimicrob Agents. 2023 Apr 14:106818.
    

    >> Share

    
    
75. ZAKHOUR J, Haddad SF, Kerbage A, Heiman W, et al
    Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance.
    Int J Antimicrob Agents. 2023 Apr 13:106816.
    

    >> Share

    
    
76. CHANG CY, Lee YL, Huang YT, Ko WC, et al
    In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
    Int J Antimicrob Agents. 2023 Apr 12:106815.
    

    >> Share

    
    
77. TRECARICHI EM, Giuliano G, Cattaneo C, Ballanti S, et al
    Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey.
    Int J Antimicrob Agents. 2023 Apr 6:106806.
    

    >> Share

    
    
78. JO J, Park W, Kweon DH, Ko KS, et al
    Development mechanism of resistant population post-exposure to tigecycline in tigecycline-heteroresistant Acinetobacter baumannii strain.
    Int J Antimicrob Agents. 2023;61:106739.
    

    >> Share

    
    
79. EINAV S, Leone M, Martin-Loeches I
    Sepsis and antibiotics: When should we deploy a parachute?
    Int J Antimicrob Agents. 2023;61:106732.
    

    >> Share

    
    March 2023
80. YU J, Lin YT, Chen WC, Tseng KH, et al
    Direct prediction of carbapenem-resistant, carbapenemase-producing, and colistin-resistant Klebsiella pneumoniae isolates from routine MALDI-TOF mass spectra using machine learning and outcome evaluation.
    Int J Antimicrob Agents. 2023 Mar 31:106799.
    

    >> Share

    
    
81. FORTUNATO G, Vaz-Moreira I, Gajic I, Manaia CM, et al
    Insight into phylogenomic bias of bla(VIM-2) or bla(NDM-1) dissemination amongst carbapenem resistant Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2023 Mar 14:106788.
    

    >> Share

    
    
82. XIU L, Wang L, Li Y, Hu L, et al
    Multicentre Clinical Evaluation of a Molecular Diagnostic Assay to Identify Neisseria gonorrhoeae Infection and Detect Antimicrobial Resistance.
    Int J Antimicrob Agents. 2023 Mar 12:106785.
    

    >> Share

    
    
83. ZHAO X, Li S, Zhang Y, Wang J, et al
    Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2023 Mar 9:106777.
    

    >> Share

    
    
84. SALADINI F, Giammarino F, Maggiolo F, Ferrara M, et al
    Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
    Int J Antimicrob Agents. 2023;61:106737.
    

    >> Share

    
    
85. HAGHANI I, Yahyazadeh Z, Hedayati MT, Shokohi T, et al
    Antifungal activity of miltefosine against both azole-susceptible and -resistant Aspergillus strains.
    Int J Antimicrob Agents. 2023;61:106715.
    

    >> Share

    
    February 2023
86. CATTEAU L, Iglesias YD, Tsunemoto H, Pogliano J, et al
    Nafcillin Augmentation of Daptomycin and Cathelicidin LL-37 Killing of Methicillin-resistant Staphylococcus epidermidis: Foundations of Successful Therapy of Endocarditis.
    Int J Antimicrob Agents. 2023 Feb 10:106758.
    

    >> Share

    
    
87. PU D, Zhao J, Lu B, Zhang Y, et al
    Within-host resistance evolution of a fatal ST11 hypervirulent carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2023 Feb 7:106747.
    

    >> Share

    
    
88. CHEN CH, Wu PH, Lu MC, Ho MW, et al
    National surveillance of antimicrobial susceptibilities to ceftaroline, dalbavancin, telavancin, tedizolid, eravacycline, omadacycline, and other comparator antibiotics and genetic characteristics of bacteremic Staphylococcus aureus isolates in adults
    Int J Antimicrob Agents. 2023 Feb 7:106745.
    

    >> Share

    
    
89. YU W, Zhang H, Zhu Y, Jia P, et al
    In vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016-2019 in China.
    Int J Antimicrob Agents. 2023 Feb 1:106741.
    

    >> Share

    
    
90. KARRULI A, Massa A, Andini R, Marrazzo T, et al
    Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience.
    Int J Antimicrob Agents. 2023;61:106723.
    

    >> Share

    
    
91. HUMPHRIES RM, Janssen H, Hey-Hadavi JH, Hackel M, et al
    Multidrug-resistant Gram-negative bacilli recovered from respiratory and blood specimens from adults: the ATLAS surveillance program in European hospitals, 2018-2020.
    Int J Antimicrob Agents. 2023;61:106724.
    

    >> Share

    
    January 2023
92. PATEL D, Brown ML, Edwards S, Oster RA, et al
    Outcomes of Daptomycin Plus Ceftaroline Versus Alternative Therapy for Persistent Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia.
    Int J Antimicrob Agents. 2023 Jan 20:106735.
    

    >> Share

    
    
93. MALIN JJ, von Wintersdorff CJH, Penders J, Savelkoul PHM, et al
    Longitudinal fluctuations of common antimicrobial resistance genes in the gut microbiomes of healthy Dutch individuals.
    Int J Antimicrob Agents. 2023 Jan 11:106716.
    

    >> Share

    
    
94. RHOUMA M, Madec JY, Laxminarayan R
    Colistin: From the shadows to a One Health approach for addressing antimicrobial resistance.
    Int J Antimicrob Agents. 2023 Jan 11:106713.
    

    >> Share

    
    
95. CHEN CH, Wu PH, Lu MC, Ho MW, et al
    Geographic patterns of carbapenem-resistant, multidrug-resistant, and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
    Int J Antimicrob Agents. 2023 Jan 3:106707.
    

    >> Share

    
    
96. NYAMANKOLLY E, Bellecave P, Wittkop L, Le Marec F, et al
    Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
    Int J Antimicrob Agents. 2023;61:106696.
    

    >> Share

    
    December 2022
97. MEZCORD V, Wong O, Pasteran F, Corso A, et al
    Role of beta-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species.
    Int J Antimicrob Agents. 2022 Dec 2:106700.
    

    >> Share

    
    
98. GATTI M, Pascale R, Cojutti PG, Rinaldi M, et al
    A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime/avibactam in a case series of renal critically ill patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-as
    Int J Antimicrob Agents. 2022 Dec 1:106699.
    

    >> Share

    
    November 2022
99. WOHLFARTH E, Kresken M, Higgins PG, Stefanik D, et al
    The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany, 2010-2019.
    Int J Antimicrob Agents. 2022 Nov 11:106689.
    

    >> Share

    
    
100. KAMUS L, Auger G, Gambarotto K, Houivet J, et al
     Investigation of a vanA linezolid- and vancomycin-resistant Enterococcus faecium outbreak in the Southwest Indian Ocean (Reunion Island).
     Int J Antimicrob Agents. 2022;60.
     

     >> Share

     
     
101. GUENEAU R, Joannard B, Haddad N, Alby F, et al
     Extensive dermatophytosis caused by terbinafine-resistant Trichophyton indotineae, successfully treated with topical voriconazole.
     Int J Antimicrob Agents. 2022;60.
     

     >> Share

     
     
102. FAN F, Liu Y, Liu Y, Lv R, et al
     Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies.
     Int J Antimicrob Agents. 2022;60.
     

     >> Share

     
     
103. GEUSAU A, Chromy D, Heissenberger D, Lippert K, et al
     Resistance profiles of Neisseria gonorrhoeae isolates in Vienna, Austria: a phenotypic and genetic characterization from 2013 to 2020.
     Int J Antimicrob Agents. 2022;60.
     

     >> Share

     
     
104. WANG P, Liu D, Sun T, Zhang X, et al
     Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
     Int J Antimicrob Agents. 2022;60.
     

     >> Share

     
     October 2022
105. HUANG YS, Sun HY, Chang SY, Chuang YC, et al
     Virological Responses to Tenofovir Alafenamide-Containing Antiretroviral Therapy in People Living with HIV Who Had Lamivudine-Resistant and Lamivudine-Susceptible Hepatitis B Virus Coinfection.
     Int J Antimicrob Agents. 2022 Oct 21:106682.
     

     >> Share

     
     
106. TANG R, Luo R, Tang S, Song H, et al
     Machine learning in predicting antimicrobial resistance: a systematic review and meta-analysis.
     Int J Antimicrob Agents. 2022 Oct 21:106684.
     

     >> Share

     
     
107. LEE YL, Ko WC, Hsueh PR
     Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Survei
     Int J Antimicrob Agents. 2022 Oct 11:106679.
     

     >> Share

     
     
108. ANTONELLI A, Coppi M, Tellapragada C, Hasan B, et al
     Isothermal microcalorimetry vs checkerboard assay to evaluate in-vitro synergism of meropenem-amikacin and meropenem-colistin combinations against multi-drug-resistant Gram-negative pathogens.
     Int J Antimicrob Agents. 2022;60:106668.
     

     >> Share

     
     
109. PHUADRAKSA T, Wichit S, Arikit S, Songtawee N, et al
     Co-occurrence of mcr-2 and mcr-3 genes on chromosome of multidrug-resistant Escherichia coli isolated from healthy individuals in Thailand.
     Int J Antimicrob Agents. 2022;60:106662.
     

     >> Share

     
     
110. GYSIN M, Hon PY, Tan P, Sengduangphachanh A, et al
     Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia.
     Int J Antimicrob Agents. 2022;60:106659.
     

     >> Share

     
     
111. LAN P, Lu Y, Jiang Y, Wu X, et al
     Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae.
     Int J Antimicrob Agents. 2022;60:106646.
     

     >> Share

     
     
112. ZHOU H, Wang S, Wu Y, Dong N, et al
     Carriage of the mcr-9 and mcr-10 genes in clinical strains of the Enterobacter cloacae complex in China: a prevalence and molecular epidemiology study.
     Int J Antimicrob Agents. 2022;60:106645.
     

     >> Share

     
     September 2022
113. LU Y, Liu JH, Yue C, Bergen PJ, et al
     Overexpression of mcr-1 disrupts cell envelope synthesis and causes the dysregulation of carbon metabolism, redox balance and nucleic acids.
     Int J Antimicrob Agents. 2022;60:106643.
     

     >> Share

     
     
114. STELLA G, Volpicelli L, Carlo DD, Vicenti I, et al
     Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV.
     Int J Antimicrob Agents. 2022;60:106636.
     

     >> Share

     
     
115. KANJ SS, Bassetti M, Kiratisin P, Rodrigues C, et al
     Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
     Int J Antimicrob Agents. 2022;60:106633.
     

     >> Share

     
     August 2022
116. SIMITSOPOULOU M, Kadiltzoglou P, Antachopoulos C, Roilides E, et al
     Daptomycin exerts differential immunomodulatory effects on host responses against methicillin-resistant Staphylococcus aureus biofilms.
     Int J Antimicrob Agents. 2022 Aug 26:106666.
     

     >> Share

     
     
117. HAJ CE, Benavent E, Sierra Y, Soldevila L, et al
     Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus.
     Int J Antimicrob Agents. 2022 Aug 21:106664.
     

     >> Share

     
     
118. YEH TK, Lin HJ, Liu PY, Wang JH, et al
     Antibiotic resistance in Enterobacter hormaechei.
     Int J Antimicrob Agents. 2022 Aug 4:106650.
     

     >> Share

     
     
119. WANG X, Wang Y, Jiang X, Gong X, et al
     Co-transfer of mcr-8 with blaNDM-1 or tmexCD1-toprJ1 by plasmid hybridisation.
     Int J Antimicrob Agents. 2022;60:106619.
     

     >> Share

     
     
120. TISEO G, Brigante G, Giacobbe DR, Maraolo AE, et al
     Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrob
     Int J Antimicrob Agents. 2022;60:106611.
     

     >> Share

     
     
121. SACCO F, Raponi G, Oliva A, Bibbolino G, et al
     An outbreak sustained by ST15 Klebsiella pneumoniae carrying 16S rRNA methyltransferases and blaNDM: evaluation of the global dissemination of these resistance determinants.
     Int J Antimicrob Agents. 2022;60:106615.
     

     >> Share

     
     June 2022
122. XIE M, Chen K, Chan EW, Zhang R, et al
     Characterization of clinical carbapenem-resistant K1 Klebsiella quasipneumoniae subsp. similipneumoniae strains harboring virulence plasmid.
     Int J Antimicrob Agents. 2022 Jun 24:106628.
     

     >> Share

     
     
123. JUAN CH, Chou SH, Chen IR, Yang CI, et al
     Intestinal colonisation with hypervirulent or third-generation cephalosporin-resistant Klebsiella pneumoniae strains upon hospital admission in a general ward in Taiwan.
     Int J Antimicrob Agents. 2022 Jun 18:106624.
     

     >> Share

     
     
124. JEAN SS, Lee YL, Hsu CW, Hsueh PR, et al
     In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-beta-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership
     Int J Antimicrob Agents. 2022 Jun 16:106617.
     

     >> Share

     
     
125. BEMER P, Aubry A, Tessier E, d'Epenoux LR, et al
     Emergence of methicillin resistant Staphylococcus epidermidis resistant to linezolid: activity of ceftaroline versus ceftobiprole in a French University French Hospital.
     Int J Antimicrob Agents. 2022 Jun 9:106613.
     

     >> Share

     
     
126. ZHOU ZL, Tseng KY, Chen YZ, Tsai DJ, et al
     Genetic relatedness among azole-resistant Candida tropicalis clinical strains in Taiwan from 2014 to 2018.
     Int J Antimicrob Agents. 2022;59:106592.
     

     >> Share

     
     
127. ELIAS R, Spadar A, Phelan J, Melo-Cristino J, et al
     A phylogenomic approach for the analysis of colistin resistance-associated genes in Klebsiella pneumoniae, its mutational diversity and implications for phenotypic resistance.
     Int J Antimicrob Agents. 2022;59:106581.
     

     >> Share

     
     May 2022
128. KIM JH, Kim TS, Chang E, Kang CK, et al
     Effectiveness of antimicrobial stewardship programmes based on rapid antibiotic susceptibility testing of haematologic patients having high-risk factors for bacteraemia related mortality: A post-hoc analysis of an RCT.
     Int J Antimicrob Agents. 2022 May 16:106604.
     

     >> Share

     
     
129. YU Y, Zhao H, Lin J, Li Z, et al
     Repurposing Non-Antibiotic Drugs Auranofin and Pentamidine in Combination to Combat Multidrug-Resistant Gram-Negative Bacteria.
     Int J Antimicrob Agents. 2022;59:106582.
     

     >> Share

     
     
130. LIAO W, Cui Y, Quan J, Zhao D, et al
     High prevalence of colistin resistance and mcr-9/10 genes in Enterobacter spp. in a tertiary hospital over a decade.
     Int J Antimicrob Agents. 2022;59:106573.
     

     >> Share

     
     April 2022
131. KOMEDA T, Shrestha S, Sherchan JB, Tohya M, et al
     Emergence of a highly colistin-resistant Aeromonas jandaei clinical isolate harbouring four genes encoding phosphoethanolamine transferases in Nepal.
     Int J Antimicrob Agents. 2022;59:106544.
     

     >> Share

     
     March 2022
132. XU T, Zhou F, Wang L, Wu S, et al
     Metronidazole-Resistant Clostridioides difficile: Genomic and Transcriptomic Traits Acquired under In vitro Metronidazole Induction.
     Int J Antimicrob Agents. 2022 Mar 13:106570.
     

     >> Share

     
     
133. JOZEFIKOVA A, Valcek A, Soltys K, Novakova E, et al
     Persistence and multi-ward dissemination of vancomycin resistant Enterococcus faecium ST17 clone in hospital settings in Slovakia from 2017 to 2020.
     Int J Antimicrob Agents. 2022 Mar 7:106561.
     

     >> Share

     
     
134. BALANDIN B, Ballesteros D, Pintado V, Soriano-Cuesta C, et al
     Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.
     Int J Antimicrob Agents. 2022;59:106536.
     

     >> Share

     
     
135. AHMADI A, Mohammadnejadi E, Karami P, Razzaghi-Asl N, et al
     Current Status and Structure Activity Relationship of Privileged Azoles as Antifungal Agents (2016-2020).
     Int J Antimicrob Agents. 2022;59:106518.
     

     >> Share

     
     February 2022
136. ASLAN AT, Kirbas E, Sancak B, Tanriverdi ES, et al
     A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
     Int J Antimicrob Agents. 2022 Feb 14:106554.
     

     >> Share

     
     
137. WANG J, Jiang Y, Ji RY, Wang ZY, et al
     Colistin- and tigecycline-resistant CTX-M-14-producing Salmonella enterica serovar Kentucky ST198 from retail chicken meat, China.
     Int J Antimicrob Agents. 2022;59:106504.
     

     >> Share

     
     
138. FONSECA EL, Morgado SM, Caldart RV, Freitas F, et al
     Emergence of a VIM-2-producing extensively drug-resistant (XDR) Pseudomonas aeruginosa ST309 in South America: a comparative genomic analysis.
     Int J Antimicrob Agents. 2022;59:106507.
     

     >> Share

     
     
139. NANG SC, Li M, Harper M, Mandela E, et al
     Polymyxin causes cell envelope remodelling and stress responses in mcr-1-harbouring Escherichia coli.
     Int J Antimicrob Agents. 2022;59:106505.
     

     >> Share

     
     
140. GUZMAN-PUCHE J, Perez-Nadales E, Perez-Vazquez M, Causse M, et al
     In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
     Int J Antimicrob Agents. 2022;59:106524.
     

     >> Share

     
     January 2022
141. HUANG YC, Chen CJ
     USA 300 (sequence type 8) became a major clone of methicillin-resistant Staphylococcus aureus in northern Taiwan.
     Int J Antimicrob Agents. 2022 Jan 25:106534.
     

     >> Share

     
     
142. DOBBYN D, Zeggil T, Kudrowich B, Beahm NP, et al
     Ciprofloxacin Resistances Rates in Escherichia coli Across Canada (CREAC): A Longitudinal Analysis 2015-2019.
     Int J Antimicrob Agents. 2022 Jan 25:106532.
     

     >> Share

     
     
143. WANG WY, Hsueh PR, Tsao SM
     Genotyping of methicillin-resistant Staphylococcus aureus isolates causing invasive infections using spa typing and their correlation with antibiotic susceptibility.
     Int J Antimicrob Agents. 2022 Jan 15:106525.
     

     >> Share

     
     
144. ARMENIA D, Santoro MM, Bellocchi MC, Carioti L, et al
     Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV.
     Int J Antimicrob Agents. 2022;59:106492.
     

     >> Share

     
     
145. PAN Y, Zeng Z, Niu H, Huang L, et al
     Whole-genome epidemiology and characterisation of mcr-1-encoding Escherichia coli in aquatic bird farms from the Pearl River Delta, China, 2019-2020.
     Int J Antimicrob Agents. 2022;59:106478.
     

     >> Share

     
     
146. KAWAMOTO Y, Kaku N, Akamatsu N, Sakamoto K, et al
     The surveillance of colistin resistance and mobilized colistin resistance genes in multidrug-resistant Enterobacteriaceae isolated in Japan.
     Int J Antimicrob Agents. 2022;59:106480.
     

     >> Share

     
     
147. YEH TK, Jean SS, Lee YL, Lu MC, et al
     Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy.
     Int J Antimicrob Agents. 2022;59:106475.
     

     >> Share

     
     
148. LUO YC, Hsieh YC, Wu JW, Quyen TLT, et al
     Exploring the association between capsular types, sequence types, and carbapenemase genes in Acinetobacter baumannii.
     Int J Antimicrob Agents. 2022;59:106470.
     

     >> Share

     
     
149. ARCA-SUAREZ J, Rodino-Janeiro BK, Perez A, Guijarro-Sanchez P, et al
     Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing.
     Int J Antimicrob Agents. 2022;59:106456.
     

     >> Share

     
     December 2021
150. LEE SS, Cheng KF, Wong NS, Kwan CK, et al
     The emergence of antibiotic resistant Mycoplasma genitalium as the cause of non-gonococcal urethritis in male sexually transmitted infection clinic patients.
     Int J Antimicrob Agents. 2021 Dec 28:106510.
     

     >> Share

     
     
151. WEI L, Feng Y, Wen H, Ya H, et al
     NDM-5-producing carbapenem-resistant Klebsiella pneumoniae of sequence type 789 emerged as a threat for neonates: a multi-center genome-based study.
     Int J Antimicrob Agents. 2021 Dec 24:106508.
     

     >> Share

     
     
152. GARZA M, Mohan CV, Brunton L, Wieland B, et al
     Typology of interventions for antimicrobial use and antimicrobial resistance in aquaculture systems in LMICs.
     Int J Antimicrob Agents. 2021 Dec 9:106495.
     

     >> Share

     
     
153. WESTERHOLT M, Hasman H, Hansen DS, Roer L, et al
     Screening patients at admission to Copenhagen hospitals for carriage of resistant bacteria after contact with healthcare systems abroad, 2016-2019.
     Int J Antimicrob Agents. 2021;58:106452.
     

     >> Share

     
     
154. KIM JS, Yu JK, Jeon SJ, Park SH, et al
     Dissemination of an international high-risk clone of Escherichia coli ST410 co-producing NDM-5 and OXA-181 carbapenemases in Seoul, Republic of Korea.
     Int J Antimicrob Agents. 2021;58:106448.
     

     >> Share

     
     
155. RECIO R, Viedma E, Gonzalez-Bodi S, Villa J, et al
     Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia.
     Int J Antimicrob Agents. 2021;58:106450.
     

     >> Share

     
     
156. YOSHIKAWA Y, Feldhaus I, Ozcelik E, Hashiguchi TCO, et al
     Financial strategies targeting healthcare providers to promote the prudent use of antibiotics: a systematic review of the evidence.
     Int J Antimicrob Agents. 2021;58:106446.
     

     >> Share

     
     November 2021
157. SEIFERT H, von Linstow ML, Janssen H, Dowzicky M, et al
     Antimicrobial Susceptibility among Gram-Negative Isolates in Pediatric Patients in Europe from 2013-2018 Compared to 2004-2012: Results from the ATLAS Surveillance Study.
     Int J Antimicrob Agents. 2021;58:106441.
     

     >> Share

     
     
158. CEBRIAN R, Xu C, Xia Y, Wu W, et al
     The cathelicidin-derived close-to-nature peptide D-11 sensitises Klebsiella pneumoniae to a range of antibiotics in vitro, ex vivo and in vivo.
     Int J Antimicrob Agents. 2021;58:106434.
     

     >> Share

     
     
159. ZHU C, Li C, Lai CKC, Ng R, et al
     Longitudinal Genomic Characterization of Carbapenemase-producing Enterobacteriaceae (CPE) Reveals Changing Pattern of CPE Isolated in Hong Kong Hospitals.
     Int J Antimicrob Agents. 2021;58:106430.
     

     >> Share

     
     
160. GIUFRE M, Mazzolini E, Cerquetti M, Brusaferro S, et al
     Extended-spectrum beta-lactamase-producing Escherichia coli from extraintestinal infections in humans and from food-producing animals in Italy: a 'One Health' study.
     Int J Antimicrob Agents. 2021;58:106433.
     

     >> Share

     
     
161. RODRIGUEZ-SANTIAGO J, Cornejo-Juarez P, Silva-Sanchez J, Garza-Ramos U, et al
     Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas.
     Int J Antimicrob Agents. 2021;58:106426.
     

     >> Share

     
     
162. LENZI MH, Martins WM, Roch M, Ramos PL, et al
     A new mutation in mgrb mediating polymyxin resistance in Klebsiella variicola.
     Int J Antimicrob Agents. 2021;58:106424.
     

     >> Share

     
     October 2021
163. BOAS DO PRADO GV, Mendes ET, Martins RCR, Perdigao-Neto LV, et al
     Phenotypic and genotypic characteristics of a Carbapenem-resistant Serratia marcescens cohort and outbreak: describing an opportunistic pathogen.
     Int J Antimicrob Agents. 2021 Oct 26:106463.
     

     >> Share

     
     
164. UDE Z, Flothkotter N, Sheehan G, Brennan M, et al
     Multi-Targeted Metallo-Ciprofloxacin Derivatives Rationally Designed and Developed to Overcome Antimicrobial Resistance.
     Int J Antimicrob Agents. 2021 Oct 10:106449.
     

     >> Share

     
     
165. CHEN T, Fu Y, Hua X, Xu Q, et al
     Acinetobacter baumannii strains isolated from cerebrospinal fluid (CSF) and bloodstream analysed by cgMLST: the dominance of clonal complex CC92 in CSF infections.
     Int J Antimicrob Agents. 2021;58:106404.
     

     >> Share

     
     
166. MILTGEN G, Bour M, Allyn J, Allou N, et al
     Molecular and epidemiological investigation of a colistin-resistant OXA-23-/NDM-1-producing Acinetobacter baumannii outbreak in the Southwest Indian Ocean Area.
     Int J Antimicrob Agents. 2021;58:106402.
     

     >> Share

     
     
167. SALVATO RS, Reis AJ, Schiefelbein SH, Gomez MAA, et al
     Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil.
     Int J Antimicrob Agents. 2021;58:106401.
     

     >> Share

     
     September 2021
168. MAGALLON J, Vu P, Reeves C, Kwan S, et al
     Amikacin in combination with zinc pyrithione prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae isolate.
     Int J Antimicrob Agents. 2021 Sep 19:106442.
     

     >> Share

     
     
169. CASTANHEIRA M, Doyle TB, Deshpande LM, Mendes RE, et al
     Activity of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem-Relebactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals.
     Int J Antimicrob Agents. 2021 Sep 18:106439.
     

     >> Share

     
     
170. RUSSO A, Venditti M
     Vertebral osteomyelitis caused by vancomycin-resistant Enterococcus spp: a case series.
     Int J Antimicrob Agents. 2021 Sep 12:106432.
     

     >> Share

     
     
171. FOLETTO VS, da Rosa TF, Serafin MB, Bottega A, et al
     Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review.
     Int J Antimicrob Agents. 2021;58:106380.
     

     >> Share

     
     
172. MULDER M, Arp PP, Kiefte-de Jong JC, Uitterlinden AG, et al
     Prevalence of and risk factors for extended-spectrum beta-lactamase genes carriership in a population-based cohort of middle-aged and elderly.
     Int J Antimicrob Agents. 2021;58:106388.
     

     >> Share

     
     
173. MORENO-MINGORANCE A, Espinal P, Rodriguez V, Goterris L, et al
     Circulation of multi-drug-resistant Shigella sonnei and Shigella flexneri among men who have sex with men in Barcelona, Spain, 2015-2019.
     Int J Antimicrob Agents. 2021;58:106378.
     

     >> Share

     
     
174. FRATONI AJ, Kuti JL, Nicolau DP
     Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration.
     Int J Antimicrob Agents. 2021;58:106395.
     

     >> Share

     
     
175. FUENTES-CASTILLO D, Shiva C, Lincopan N, Sano E, et al
     Global high-risk clone of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae ST307 emerging in livestock in Peru.
     Int J Antimicrob Agents. 2021;58:106389.
     

     >> Share

     
     August 2021
176. KIM JS, Yu JK, Jeon SJ, Park SH, et al
     Distribution of mcr genes among carbapenem-resistant Enterobacterales clinical isolates: High prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea.
     Int J Antimicrob Agents. 2021 Aug 12:106418.
     

     >> Share

     
     
177. ALLEN GP, Deao KM, Hill SA, Schipelliti SM, et al
     In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
     Int J Antimicrob Agents. 2021 Aug 12:106417.
     

     >> Share

     
     
178. IWU CD, Patrick SM
     An insight into the Implementation of the Global Action Plan on Antimicrobial Resistance in the WHO African Region: A Roadmap for Action.
     Int J Antimicrob Agents. 2021 Aug 6:106411.
     

     >> Share

     
     
179. LU S, Li D, Wang L, Bi Y, et al
     Promoter variations associated with expression of mcr-1 gene and level of colistin resistance.
     Int J Antimicrob Agents. 2021;58:106371.
     

     >> Share

     
     
180. LI J, Roberts J
     Antibiotic pharmacokinetics/pharmacodynamics: where are we heading?
     Int J Antimicrob Agents. 2021;58:106369.
     

     >> Share

     
     
181. JUNCO SJ, Bowman MC, Turner RB
     Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
     Int J Antimicrob Agents. 2021;58:106367.
     

     >> Share

     
     
182. RAO GG, Landersdorfer CB
     Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond.
     Int J Antimicrob Agents. 2021;58:106368.
     

     >> Share

     
     July 2021
183. WARETH G, Linde J, Hammer P, Nguyen NH, et al
     Corrigendum to "Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam" [International Journal of Antimicrobial Agents, Volume 56, Issue 4, October 2020, 1061
     Int J Antimicrob Agents. 2021 Jul 26:106407.
     

     >> Share

     
     
184. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
     Erratum to "Impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries. A systematic review" [International Journal of Antimicrobial Agents (2021) Volume 58, Issue 1/106364].
     Int J Antimicrob Agents. 2021 Jul 14:106396.
     

     >> Share

     
     
185. ANTONELLO RM, Di Bella S, Betts J, La Ragione R, et al
     Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales.
     Int J Antimicrob Agents. 2021;58:106362.
     

     >> Share

     
     
186. LAI CC, Yu WL
     Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998-2019.
     Int J Antimicrob Agents. 2021;58:106354.
     

     >> Share

     
     June 2021
187. LEE YL, Ko WC, Lee WS, Lu PL, et al
     In vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline, and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Res
     Int J Antimicrob Agents. 2021 Jun 21:106377.
     

     >> Share

     
     
188. CHAIYACHAT P, Chaiprasert A, Nonghanphithak D, Smithtikarn S, et al
     Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance.
     Int J Antimicrob Agents. 2021 Jun 20:106385.
     

     >> Share

     
     
189. MOOR J, Aebi S, Rickli S, Mostacci N, et al
     Dynamics of extended-spectrum cephalosporin-resistant E. coli in pig farms: A longitudinal study.
     Int J Antimicrob Agents. 2021 Jun 19:106382.
     

     >> Share

     
     
190. TIMMERMANS M, Wattiau P, Denis O, Boland C, et al
     Colistin resistance genes mcr-1 to mcr-5, including a case of triple occurrence (mcr-1, -3 and -5), in Escherichia coli isolates from faeces of healthy pigs, cattle and poultry in Belgium, 2012-2016.
     Int J Antimicrob Agents. 2021;57:106350.
     

     >> Share

     
     
191. CLERICI D, Oltolini C, Greco R, Ripa M, et al
     The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
     Int J Antimicrob Agents. 2021;57:106335.
     

     >> Share

     
     
192. ALMANGOUR TA, Garcia E, Zhou Q, Forrest A, et al
     Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
     Int J Antimicrob Agents. 2021;57:106328.
     

     >> Share

     
     May 2021
193. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
     What is the impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries? A systematic review: AR after mass/systematic antibiotic administration.
     Int J Antimicrob Agents. 2021 May 24:106364.
     

     >> Share

     
     
194. DELORY T, Gravier S, Pluart DL, Gaube G, et al
     Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
     Int J Antimicrob Agents. 2021 May 14:106361.
     

     >> Share

     
     
195. TSAI HY, Lee YL, Liu PY, Lu MC, et al
     Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019/2020 Nationwide Surveillance of Multicenter Antimicrobial Re
     Int J Antimicrob Agents. 2021 May 4:106353.
     

     >> Share

     
     
196. MEI CY, Wu H, Wang Y, Wang ZY, et al
     First detection of the multiresistance gene cfr in Escherichia coli from retail vegetables, China.
     Int J Antimicrob Agents. 2021;57:106348.
     

     >> Share

     
     
197. MBHELE N, Chimukangara B, Gordon M
     HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
     Int J Antimicrob Agents. 2021;57:106343.
     

     >> Share

     
     
198. WANG X, Ling Z, Sun N, Liu Y, et al
     Molecular genetic characteristics of mcr-9-harbouring Salmonella enterica serotype Typhimurium isolated from raw milk.
     Int J Antimicrob Agents. 2021;57:106332.
     

     >> Share

     
     
199. NGUYEN HT, Venter H, Veltman T, Williams R, et al
     In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens.
     Int J Antimicrob Agents. 2021;57:106323.
     

     >> Share

     
     
200. MUSHTAQ S, Garello P, Vickers A, Woodford N, et al
     Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
     Int J Antimicrob Agents. 2021;57:106318.
     

     >> Share

     
     April 2021
201. KOSTYANEV T, Xavier BB, Garcia-Castillo M, Lammens C, et al
     Phenotypic and Molecular Characterisations of Carbapenem-resistant Acinetobacter baumannii Isolates Collected within the EURECA Study.
     Int J Antimicrob Agents. 2021 Apr 19:106345.
     

     >> Share

     
     
202. HUANG PH, Cheng YH, Chen WY, Juan CH, et al
     Risk factors and mechanisms of in vivo emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae.
     Int J Antimicrob Agents. 2021 Apr 14:106342.
     

     >> Share

     
     
203. CREMET L, Leroy AG, Muller D, Delanou S, et al
     Antibiotic Resistance Heterogeneity and LasR Diversity within Pseudomonas aeruginosa Populations from Pneumonia in Intensive Care Unit Patients.
     Int J Antimicrob Agents. 2021 Apr 12:106341.
     

     >> Share

     
     
204. SCUDELLER L, Righi E, Chiamenti M, Bragantini D, et al
     Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
     Int J Antimicrob Agents. 2021 Apr 12:106344.
     

     >> Share

     
     
205. TANG SSL, Chee E, Teo JQ, Chlebicki MP, et al
     Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study.
     Int J Antimicrob Agents. 2021 Apr 12:106340.
     

     >> Share

     
     
206. KLEIN S, Boutin S, Heeg K, Zanger P, et al
     Genomic structure of ST8-t008 USA300 and USA300-LV MRSA in the Rhine-Neckar Region, Germany, 2012-2018.
     Int J Antimicrob Agents. 2021;57:106312.
     

     >> Share

     
     
207. HERRERA M, Gregorio SD, Haim MS, Posse G, et al
     Genetic changes associated with tigecycline resistance in Staphylococcus aureus in vitro-selected mutants belonging to different lineages.
     Int J Antimicrob Agents. 2021;57:106304.
     

     >> Share

     
     March 2021
208. BONNIN RA, Girlich D, Jousset AB, Emeraud C, et al
     Genomic analysis of VIM-2-producing Enterobacter hormaechei subsp. steigerwaltii.
     Int J Antimicrob Agents. 2021;57:106285.
     

     >> Share

     
     
209. NI M, Zhao L, Zhang WJ, Ma JW, et al
     Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration alone in intracranial infections.
     Int J Antimicrob Agents. 2021;57:106281.
     

     >> Share

     
     
210. JOHNSON MG, Bruno C, Castanheira M, Yu B, et al
     Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
     Int J Antimicrob Agents. 2021;57:106278.
     

     >> Share

     
     
211. VAN BILSEN WPH, van Dulm E, Matser A, Linde I, et al
     High carriage of ESBL-producing Enterobacteriaceae associated with sexual activity among men who have sex with men.
     Int J Antimicrob Agents. 2021;57:106276.
     

     >> Share

     
     
212. BALANDIN B, Ballesteros D, Ruiz de Luna R, Lopez-Vergara L, et al
     Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
     Int J Antimicrob Agents. 2021;57:106270.
     

     >> Share

     
     
213. CIMOLAI N
     Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences.
     Int J Antimicrob Agents. 2021;57:106257.
     

     >> Share

     
     
214. CIMOLAI N
     Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences.
     Int J Antimicrob Agents. 2021;57:106258.
     

     >> Share

     
     February 2021
215. HERNANDEZ-GARCIA M, Garcia-Fernandez S, Garcia-Castillo M, Melo-Cristino J, et al
     Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
     Int J Antimicrob Agents. 2021;57:106259.
     

     >> Share

     
     
216. CHERNOVA OA, Chernov VM, Mouzykantov AA, Baranova NB, et al
     Antimicrobial drug resistance mechanisms among Mollicutes.
     Int J Antimicrob Agents. 2021;57:106253.
     

     >> Share

     
     
217. XU Q, Sheng Z, Hao M, Jiang J, et al
     RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in Klebsiella pneumoniae.
     Int J Antimicrob Agents. 2021;57:106251.
     

     >> Share

     
     
218. LOMBARDI F, Giacomelli A, Armenia D, Lai A, et al
     Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database.
     Int J Antimicrob Agents. 2021;57:106252.
     

     >> Share

     
     
219. GOMEZ-JUNYENT J, Murillo O, Yu HH, Azad MAK, et al
     In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
     Int J Antimicrob Agents. 2021;57:106246.
     

     >> Share

     
     January 2021
220. PICCIRILLI A, Segatore B, Brisdelli F, Amicosante G, et al
     Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1(Q119X) mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales.
     Int J Antimicrob Agents. 2021;57:106228.
     

     >> Share

     
     
221. HUANG L, Cao M, Hu Y, Zhang R, et al
     Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China.
     Int J Antimicrob Agents. 2021;57:106226.
     

     >> Share

     
     
222. FREITAS AR, Pereira AP, Novais C, Peixe L, et al
     Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?
     Int J Antimicrob Agents. 2021;57:106227.
     

     >> Share

     
     
223. OUCHAR MAHAMAT O, Kempf M, Lounnas M, Tidjani A, et al
     Epidemiology and prevalence of extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa.
     Int J Antimicrob Agents. 2021;57:106203.
     

     >> Share

     
     August 2020
224. IANNACCONE M, Boattini M, Bianco G, Cavallo R, et al
     Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa.
     Int J Antimicrob Agents. 2020;56:106066.
     

     >> Share

     
     
225. ANDRE-GARNIER E, Hingrat QL, Marcelin AG, Reliquet V, et al
     Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
     Int J Antimicrob Agents. 2020;56:106039.
     

     >> Share

     
     July 2020
226. MOWLABOCCUS S, Daley D, Pang S, Gottlieb T, et al
     Identification and Characterisation of Fosfomycin Resistance in Escherichia coli Urinary Tract Infection Isolates from Australia.
     Int J Antimicrob Agents. 2020 Jul 30:106121.
     

     >> Share

     
     
227. NGUYEN HM, Graber CJ
     A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of "Bad Bugs, Few Drugs".
     Int J Antimicrob Agents. 2020 Jul 10:106085.
     

     >> Share

     
     
228. MARTINS WMBS, Seco BMS, Sampaio JLM, Sands K, et al
     Detection of BKC-1 in Citrobacter freundii: A clue to mobilisation in an IncQ1 plasmid carrying blaBKC-1.
     Int J Antimicrob Agents. 2020;56:106042.
     

     >> Share

     
     
229. HSU CY, Chen FJ, Huang WC, Liao YC, et al
     Plasmid- and chromosome-located mcr-3 in mcr-1-positive Escherichia coli in Taiwan.
     Int J Antimicrob Agents. 2020;56:105996.
     

     >> Share

     
     
230. FURLAN JPR, Savazzi EA, Stehling EG
     Widespread high-risk clones of multidrug-resistant extended-spectrum beta-lactamase-producing Escherichia coli B2-ST131 and F-ST648 in public aquatic environments.
     Int J Antimicrob Agents. 2020;56:106040.
     

     >> Share

     
     
231. PEREZ-VAZQUEZ M, Sola-Campoy PJ, Zurita AM, Avila A, et al
     Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2.
     Int J Antimicrob Agents. 2020;56:106026.
     

     >> Share

     
     
232. SANTORO MM, Fornabaio C, Malena M, Galli L, et al
     Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
     Int J Antimicrob Agents. 2020;56:106027.
     

     >> Share

     
     
233. GAURAV A, Kothari A, Omar BJ, Pathania R, et al
     Assessment of polymyxin B-doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia.
     Int J Antimicrob Agents. 2020;56:106022.
     

     >> Share

     
     
234. BARBOSA F, Pinto E, Kijjoa A, Pinto M, et al
     Targeting antimicrobial drug resistance with marine natural products.
     Int J Antimicrob Agents. 2020;56:106005.
     

     >> Share

     
     
235. WILLCOCKS SJ, Cia F, Francisco AF, Wren BW, et al
     Revisiting aminocoumarins for the treatment of melioidosis.
     Int J Antimicrob Agents. 2020;56:106002.
     

     >> Share

     
     
236. CHEN L, Han D, Tang Z, Hao J, et al
     Co-existence of the oxazolidinone resistance genes cfr and optrA on two transferable multi-resistance plasmids in one Enterococcus faecalis isolate from swine.
     Int J Antimicrob Agents. 2020;56:105993.
     

     >> Share

     
     
237. KAVANAUGH LG, Flanagan JN, Steck TR
     Reciprocal antibiotic collateral sensitivity in Burkholderia multivorans.
     Int J Antimicrob Agents. 2020;56:105994.
     

     >> Share

     
     
238. DOGAN O, Yesilkaya A, Menekse S, Guler O, et al
     Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
     Int J Antimicrob Agents. 2020;56:105992.
     

     >> Share

     
     
239. NOEL A, Attwood M, Bowker K, MacGowan A, et al
     The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection.
     Int J Antimicrob Agents. 2020;56:105985.
     

     >> Share

     
     
240. STRAZZULLA A, Iordache L, de Pontfarcy A, Pitsch A, et al
     beta-Lactam allergy and risk of multidrug-resistant bacteria in the intensive care unit: A cohort study.
     Int J Antimicrob Agents. 2020;56:105979.
     

     >> Share

     
     
241. CAI T, Tamanini I, Mattevi D, Verze P, et al
     Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study.
     Int J Antimicrob Agents. 2020;56:105935.
     

     >> Share

     
     
242. PERALES C
     Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance.
     Int J Antimicrob Agents. 2020;56:105562.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share